Posted on: 23 February 2022
Marco Isetta, CNWL’s Head of Technology-Enhanced Learning, Library and Knowledge Services has contributed to a research paper on the role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in personalized treatment of patients with isolated Polymyalgia Rheumatica (PMR).
The paper highlights the limited effectiveness of anti TNF-α drugs in patients with PMR as reported in published studies. Long-term Glucocorticoid (GC) therapy for patients with PMR is known to induce many serious adverse events such as diabetes mellitus, hypertension, cataract and osteoporosis, as well as negative psychological sequelae. Alternatives to the use of GCs have long been sought, tumour necrosis-alpha inhibitors (anti TNF-α) among these.